Antimitotic Agents: all 5,052 studies that test it
Page 25 of 51. Open to participants first (616), then studies with results posted, then the rest; newest registration first within each.
- Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABGStatus unknownNCT03905759Phase 2/3
- A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeActive, not recruitingNCT03899337Phase 2
- The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as OraxolTerminatedNCT03892018Phase 1
- Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic CancerStatus unknownNCT03885219Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerCompletedNCT03872791Phase 1/2
- Improve Checkpoint-blockade Response in Advanced Urothelial CancerCompletedNCT03871036Phase 1/2
- A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast CancerStatus unknownNCT03863223Phase 3
- Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBCTerminatedNCT03858972Phase 2
- Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell LymphomaStatus unknownNCT03853044Phase 2
- Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve FertilityTerminatedNCT03852979Phase 2
- Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic CancerStatus unknownNCT03850769Phase 2
- Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast CancerStatus unknownNCT03847818Not applicable
- Eribulin in Advanced Solitary Fibrous TumorCompletedNCT03840772Phase 2
- Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine CarcinomaCompletedNCT03837977Phase 2
- DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
- AO-176 in Multiple Solid Tumor MalignanciesCompletedNCT03834948Phase 1/2
- Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive WomenWithdrawnNCT03834571Phase 2
- The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract AdenocarcinomaCompletedNCT03830606Phase 2
- A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )Status unknownNCT03825328Phase 2
- Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric CancerWithdrawnNCT03818997Phase 2
- Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian CancerStatus unknownNCT03818282Phase 2
- Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic CancerStatus unknownNCT03815461Phase 2
- A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast CancerWithdrawnNCT03811418Phase 3
- A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or LeiomyosarcomaCompletedNCT03810976Phase 2
- FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
- Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung CancerTerminatedNCT03802058Phase 2
- Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric AdenocarcinomaStatus unknownNCT03801668Phase 3
- Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung CancerCompletedNCT03801304Phase 2
- Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLCStatus unknownNCT03799601Phase 4
- Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer PatientsTerminatedNCT03795012Phase 2
- PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell CarcinomaStatus unknownNCT03791905Phase 2
- A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric CancerStatus unknownNCT03788226Phase 3
- Apatinib Combined With POF for Second-line Treatment of Gastric AdenocarcinomaStatus unknownNCT03788174Phase 2
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
- Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric CancerWithdrawnNCT03766607Phase 2
- Docetaxel Versus Cabazitaxel Post Abiraterone or EnzalutamideTerminatedNCT03764540Phase 2
- TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT03756818Phase 1
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Active, not recruitingNCT03755804Phase 2
- To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate CancerTerminatedNCT03752099Phase 1/2
- GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel StudyCompletedNCT03751761Phase 1/2
- Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung CancerStatus unknownNCT03750916Phase 2
- Paclitaxel and TAK-228 in Urothelial CarcinomaStatus unknownNCT03745911Phase 2
- Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian CancerCompletedNCT03742713Phase 2
- Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate CancerCompletedNCT03737370Phase 1
- Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.CompletedNCT03735966Phase 2
- Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）Status unknownNCT03735264Phase 2
- Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast CancerStatus unknownNCT03735082Phase 2
- ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid TumorsCompletedNCT03725436Phase 1
- FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/PaclitaxelCompletedNCT03723967Phase 2
- A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesCompletedNCT03719326Phase 1
- A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer CellsStatus unknownNCT03718624Phase 2
- DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BCActive, not recruitingNCT03716180Phase 1
- Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT03708822Phase 2
- Study of the Combination of Apatinib and POFStatus unknownNCT03707639Phase 2
- A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction CancerTerminatedNCT03707028Phase 1/2
- Rh-Endostatin (Endostar®) Continuous Intravenous InfusionStatus unknownNCT03706703Phase 2
- Colchicine for Patients With Chagas´ Disease( B1 Stage)Status unknownNCT03704181Phase 2
- An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnNCT03704077Phase 2
- Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLCStatus unknownNCT03703596Phase 2
- Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal CytologyStatus unknownNCT03703089Phase 1
- Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic CancerStatus unknownNCT03703063Phase 1
- Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by EnzalutamideActive, not recruitingNCT03700099Phase 2
- Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung CancerWithdrawnNCT03699033Phase 2
- High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic CancerWithdrawnNCT03697239Phase 1/2
- Colchicine for Amyotrophic Lateral SclerosisCompletedNCT03693781Phase 2
- First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRICompletedNCT03693677Phase 2
- Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）CompletedNCT03693547Phase 2
- Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal CancerStatus unknownNCT03693248Phase 3
- Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric AdenocarcinomaActive, not recruitingNCT03691454Phase 2/3
- Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian CancerTerminatedNCT03690739Phase 3
- Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVRCompletedNCT03659058Not applicable
- Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLCStatus unknownNCT03654027Phase 2
- Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal CancerStatus unknownNCT03649945Phase 2
- Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerCompletedNCT03647969Phase 2
- Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal CancerCompletedNCT03647839Phase 2
- Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast CancerStatus unknownNCT03647514Not applicable
- The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast CancerStatus unknownNCT03647280Not applicable
- Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian CancerCompletedNCT03639246Phase 1
- Eribulin in Brain Metastases From HER2-negative Breast CancerWithdrawnNCT03637868Phase 2
- Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung CancerStatus unknownNCT03624309Phase 2
- Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt CoursesActive, not recruitingNCT03620032Phase 2
- Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6CompletedNCT03618758Phase 1/2
- Ruxolitinib Plus LVP in Patients With R/R ETP-ALLStatus unknownNCT03613428Phase 1/2
- ANG1005 in Leptomeningeal Disease From Breast CancerStatus unknownNCT03613181Phase 3
- Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCActive, not recruitingNCT03611738Phase 1
- Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyWithdrawnNCT03607955Phase 1
- mFLOT Chemotherapy as First-line Treatment in GCCompletedNCT03606928Phase 1/2
- Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgerySuspendedNCT03604991Phase 2/3
- SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell CancerStatus unknownNCT03603756Phase 2
- Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03600831Phase 2/3
- Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast CancerCompletedNCT03600090Phase 1
- Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory OsteosarcomaActive, not recruitingNCT03598595Phase 1/2
- Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid TumorsTerminatedNCT03588039Phase 1
- Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT03587311Phase 2
- Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid TumorsTerminatedNCT03585465Phase 1/2
- Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic CancerTerminatedNCT03585062Phase 2
- A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast CancerCompletedNCT03583944Phase 4
- Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin LymphomaCompletedNCT03580408Phase 2
- Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric CancerActive, not recruitingNCT03579784Phase 2